The agency’s high-level turnover and conflicting policy decisions on drug oversight have fueled concerns about the leadership of Dr. Marty Makary.
Category: Rare and Orphan Diseases
-
Drugmakers Notch a $5 Billion Win in Republicans’ Policy Bill
More medicines will be spared from Medicare price negotiations, a change that is projected to wipe out billions in savings for the federal government.